Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2007-005037-11 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is an open-label, randomized, 2-period crossover study, to evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of warfarin in combination with Tamiflu (oseltamivir) in participants stabilized on warfarin. Participants will be randomized to receive either their warfarin followed oseltamivir and warfarin, or by oseltamivir and warfarin followed by warfarin. The treatment periods will be separated by a washout period of at least 4 days. Participants will continue receiving warfarin once daily at a prescribed usual dose throughout the study.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| First Warfarin Then Warfarin and Oseltamivir | Experimental | Participants will receive warfarin (on Days 1-5) in Treatment Period 1, followed by a washout period of at least 4 days (maximum 8 days). Participants will then receive oseltamivir 75 milligram (mg) (orally twice daily on Days 1-4 and once on Day 5) and warfarin in Treatment Period 2, and attend a follow-up visit 4-12 days after the last dose in Treatment Period 2. Participants will continue receiving warfarin once daily at a prescribed usual dose throughout the study. |
|
| First Warfarin and Oseltamivir Then Warfarin | Experimental | Participants will receive oseltamivir 75 mg (orally twice daily on Days 1-4 and once on Day 5) and warfarin in Treatment Period 1, followed by a washout period of at least 4 days (maximum 8 days). Participants will then receive warfarin (on Days 1-5) in Treatment Period 2, and attend a follow-up visit 4-12 days after the last dose in Treatment Period 2. Participants will continue receiving warfarin once daily at a prescribed usual dose throughout the study. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Oseltamivir | Drug | Oseltamivir 75 mg orally, twice daily for 4 days and once on Day 5. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Area Under the Plasma Effect-time Curve Over 96 Hours (AUEC[0-96 h]) for International Normalized Ratio (INR) | INR is calculated based on results of a prothrombin time (PT) test (which measures how long it takes blood to clot) and is used to monitor individuals who are being treated with the blood-thinning medication (anticoagulant) warfarin. The net AUEC(0-96 h) was calculated using the linear trapezoidal rule; this was the area under the effect-time curve and above the baseline minus the area above the curve and below the baseline during the 5-day period. An increase in INR signifies enhancement of warfarin's anticoagulant effect. | Pre-dose on Day 1, 24 hours (Day 2), 48 hours (Day 3), 72 hours (Day 4), and 96 hours (Day 5) |
| Change From Baseline in Maximum Observed Effect (Emax) of International Normalized Ratio (INR) | INR is calculated based on results of a prothrombin time (PT) test (which measures how long it takes blood to clot) and is used to monitor individuals who are being treated with the blood-thinning medication (anticoagulant) warfarin. An increase in INR signifies enhancement of warfarin's anticoagulant effect. | Pre-dose on Day 1, 24 hours (Day 2), 48 hours (Day 3), 72 hours (Day 4), and 96 hours (Day 5) |
| Time to Reach Maximum Change From Baseline in International Normalized Ratio (INR) (Tmax) | INR is calculated based on results of a prothrombin time (PT) test (which measures how long it takes blood to clot) and is used to monitor individuals who are being treated with the blood-thinning medication (anticoagulant) warfarin. An increase in INR signifies enhancement of warfarin's anticoagulant effect. | Pre-dose on Day 1, 24 hours (Day 2), 48 hours (Day 3), 72 hours (Day 4), and 96 hours (Day 5) |
| Area Under the Plasma Effect-time Curve Over 96 Hours (AUEC[0-96 h]) for Factor VII Activity | Factor VIIa is a protein that causes blood to clot, and low levels in the blood can cause excessive or prolonged bleeding after an injury or surgery. The net AUEC(0-96 h) was calculated using the linear trapezoidal rule; this was the area under the effect-time curve and above the baseline minus the area above the curve and below the baseline during the 5-day period. A decrease in factor VIIa activity signifies enhancement of warfarin's anticoagulant effect. kIU/L = 1000 * international units per liter. |
| Measure | Description | Time Frame |
|---|---|---|
| Time to Maximum Plasma Concentration (Tmax) for Oseltamivir and Oseltamivir Carboxylate | Oseltamivir carboxylate is an active metabolite of oseltamivir. | Pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours post-dose on Day 1 and 5; 18 and 24 hours post-dose on Day 5 |
| Time to Maximum Plasma Concentration (Tmax) for R- and S- Warfarin |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Trials | Hoffmann-La Roche | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Surrey | CR7 7YE | United Kingdom |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | First Warfarin Then Warfarin and Oseltamivir | Participants received warfarin (on Days 1-5) in Treatment Period 1, followed by a washout period of at least 4 days (maximum 8 days). Participants then received oseltamivir 75 milligram (mg) (orally twice daily on Days 1-4 and once on Day 5) and warfarin in Treatment Period 2, and attended a follow-up visit 4-12 days after the last dose in Treatment Period 2. Participants continued to receive warfarin once daily at a prescribed usual dose throughout the study. |
| FG001 | First Warfarin and Oseltamivir Then Warfarin | Participants received oseltamivir 75 mg (orally twice daily on Days 1-4 and once on Day 5) and warfarin in Treatment Period 1, followed by a washout period of at least 4 days (maximum 8 days). Participants then received warfarin (on Days 1-5) in Treatment Period 2, and attended a follow-up visit 4-12 days after the last dose in Treatment Period 2. Participants continued to receive warfarin once daily at a prescribed usual dose throughout the study. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Treatment Period 1 |
| |||||||||||||
| Treatment Period 2 |
|
Analysis was performed on all enrolled participants.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | All Participants | Participants were randomized to 1 of 2 treatment sequences: warfarin then oseltamivir 75 mg and warfarin; or oseltamivir 75 mg and warfarin then warfarin. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Area Under the Plasma Effect-time Curve Over 96 Hours (AUEC[0-96 h]) for International Normalized Ratio (INR) | INR is calculated based on results of a prothrombin time (PT) test (which measures how long it takes blood to clot) and is used to monitor individuals who are being treated with the blood-thinning medication (anticoagulant) warfarin. The net AUEC(0-96 h) was calculated using the linear trapezoidal rule; this was the area under the effect-time curve and above the baseline minus the area above the curve and below the baseline during the 5-day period. An increase in INR signifies enhancement of warfarin's anticoagulant effect. | All enrolled participants. | Posted | Mean | Full Range | hours*ratio | Pre-dose on Day 1, 24 hours (Day 2), 48 hours (Day 3), 72 hours (Day 4), and 96 hours (Day 5) |
|
Five days for each treatment period (Up to Day 26)
All enrolled participants.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Warfarin | Participants who received Warfarin alone at a prescribed usual dose in treatment period 1 or treatment period 2. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Angina pectoris | Cardiac disorders | MedDRA (11.0) | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Fungal skin infection | Infections and infestations | MedDRA (11.0) | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Medical Communications | Hoffmann-La Roche | 800 821-8590 | genentech@druginfo.com |
Not provided
| ID | Term |
|---|---|
| D053139 | Oseltamivir |
| D014859 | Warfarin |
| ID | Term |
|---|---|
| D000081 | Acetamides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D053138 | Cyclohexenes |
| D003510 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Warfarin | Drug | Warfarin once daily, at a dose determined through titration by participants' usual hematologist. |
|
| Pre-dose on Day 1, 24 hours (Day 2), 48 hours (Day 3), 72 hours (Day 4), and 96 hours (Day 5) |
| Change From Baseline in Maximum Observed Effect (Emax) in Factor VII Activity | Factor VIIa is a protein that causes blood to clot. A decrease in factor VIIa activity signifies enhancement of warfarin's anticoagulant effect. kIU/L = 1000 * international units per liter. | Pre-dose on Day 1, 24 hours (Day 2), 48 hours (Day 3), 72 hours (Day 4), and 96 hours (Day 5) |
| Time to Reach Maximum Change From Baseline in Factor VII Activity (Tmax) | Factor VIIa is a protein that causes blood to clot. A decrease in factor VIIa activity signifies enhancement of warfarin's anticoagulant effect. | Pre-dose on Day 1, 24 hours (Day 2), 48 hours (Day 3), 72 hours (Day 4), and 96 hours (Day 5) |
| Change From Baseline in Plasma Concentration of Vitamin K1 | Vitamin K1 is required by proteins involved in blood clotting. Food interaction with warfarin can lead to decreases in Vitamin K1 in plasma. An increase in vitamin K1 signifies enhancement of warfarin's anticoagulant effect. | Pre-dose on Day 1 and 24 hours post-dose on Day 5 |
| Pre-dose; 1, 2, 4, 8, 12, 24 hours post-dose on Day 5 |
| Terminal Half-life (t½) for Oseltamivir and Oseltamivir Carboxylate | Oseltamivir carboxylate is an active metabolite of oseltamivir. | Pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours post-dose on Day 1 and 5; 18 and 24 hours post-dose on Day 5 |
| Terminal Half-life (t½) for R- and S- Warfarin | Pre-dose; 1, 2, 4, 8, 12, 24 hours post-dose on Day 5 |
| Oral Plasma Clearance (CL/F) for Oseltamivir | Pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours post-dose on Day 1 and 5; 18 and 24 hours post-dose on Day 5 |
| Oral Plasma Clearance (CL/F) for R- and S- Warfarin | Pre-dose; 1, 2, 4, 8, 12, 24 hours post-dose on Day 5 |
| Maximum Plasma Concentration (Cmax) for Oseltamivir and Oseltamivir Carboxylate | Pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours post-dose on Day 1 and 5; 18 and 24 hours post-dose on Day 5 |
| Maximum Plasma Concentration (Cmax) for R- and S- Warfarin | R- and S-warfarin are two molecular versions of warfarin with slightly different structures. The reported concentrations were normalized by dividing the Cmax values (nanograms per milliliter) by the individual average dose (milligrams). | Pre-dose; 1, 2, 4, 8, 12, 24 hours post-dose on Day 5 |
| Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero to 24 Hours (AUC0-24h) for Oseltamivir and Oseltamivir Carboxylate | Pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18 and 24 hours post-dose on Day 5 |
| Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero to 24 Hours (AUC0-24h) for R- and S- Warfarin | R- and S-warfarin are two molecular versions of warfarin with slightly different structures. The reported concentrations were normalized by dividing the AUC values (hours multiplied by nanograms, per milliliter) by the individual average dose (milligrams). | Pre-dose; 1, 2, 4, 8, 12, 24 hours post-dose on Day 5 |
| Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero to 12 Hours (AUC0-12h) for Oseltamivir and Oseltamivir Carboxylate | Pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours post-dose on Day 1 and 5; 18 and 24 hours post-dose on Day 5 |
| Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero to 12 Hours (AUC0-12h) for R- and S- Warfarin | R- and S-warfarin are two molecular versions of warfarin with slightly different structures. The reported concentrations were normalized by dividing the AUC values (hours multiplied by nanograms, per milliliter) by the individual average dose (milligrams). | Pre-dose; 1, 2, 4, 8, 12, 24 hours post-dose on Day 5 |
| Percentage of Participants With Adverse Events | An adverse event was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. | Up to Day 26 |
| NOT COMPLETED |
|
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| OG001 | Warfarin and Oseltamivir | Participants who received warfarin at a prescribed usual dose along with oseltamivir 75 mg, orally twice daily on Days 1-4 and once on Day 5 in treatment period 1 or treatment period 2. |
|
|
| Primary | Change From Baseline in Maximum Observed Effect (Emax) of International Normalized Ratio (INR) | INR is calculated based on results of a prothrombin time (PT) test (which measures how long it takes blood to clot) and is used to monitor individuals who are being treated with the blood-thinning medication (anticoagulant) warfarin. An increase in INR signifies enhancement of warfarin's anticoagulant effect. | All enrolled participants. | Posted | Mean | Full Range | ratio | Pre-dose on Day 1, 24 hours (Day 2), 48 hours (Day 3), 72 hours (Day 4), and 96 hours (Day 5) |
|
|
|
| Primary | Time to Reach Maximum Change From Baseline in International Normalized Ratio (INR) (Tmax) | INR is calculated based on results of a prothrombin time (PT) test (which measures how long it takes blood to clot) and is used to monitor individuals who are being treated with the blood-thinning medication (anticoagulant) warfarin. An increase in INR signifies enhancement of warfarin's anticoagulant effect. | All enrolled participants. | Posted | Median | Full Range | hours | Pre-dose on Day 1, 24 hours (Day 2), 48 hours (Day 3), 72 hours (Day 4), and 96 hours (Day 5) |
|
|
|
| Primary | Area Under the Plasma Effect-time Curve Over 96 Hours (AUEC[0-96 h]) for Factor VII Activity | Factor VIIa is a protein that causes blood to clot, and low levels in the blood can cause excessive or prolonged bleeding after an injury or surgery. The net AUEC(0-96 h) was calculated using the linear trapezoidal rule; this was the area under the effect-time curve and above the baseline minus the area above the curve and below the baseline during the 5-day period. A decrease in factor VIIa activity signifies enhancement of warfarin's anticoagulant effect. kIU/L = 1000 * international units per liter. | All enrolled participants with available data. | Posted | Mean | Full Range | hours*kIU/L | Pre-dose on Day 1, 24 hours (Day 2), 48 hours (Day 3), 72 hours (Day 4), and 96 hours (Day 5) |
|
|
|
| Primary | Change From Baseline in Maximum Observed Effect (Emax) in Factor VII Activity | Factor VIIa is a protein that causes blood to clot. A decrease in factor VIIa activity signifies enhancement of warfarin's anticoagulant effect. kIU/L = 1000 * international units per liter. | All enrolled participants with available data. | Posted | Mean | Full Range | kIU/L | Pre-dose on Day 1, 24 hours (Day 2), 48 hours (Day 3), 72 hours (Day 4), and 96 hours (Day 5) |
|
|
|
| Primary | Time to Reach Maximum Change From Baseline in Factor VII Activity (Tmax) | Factor VIIa is a protein that causes blood to clot. A decrease in factor VIIa activity signifies enhancement of warfarin's anticoagulant effect. | All enrolled participants with available data. | Posted | Median | Full Range | hours | Pre-dose on Day 1, 24 hours (Day 2), 48 hours (Day 3), 72 hours (Day 4), and 96 hours (Day 5) |
|
|
|
| Primary | Change From Baseline in Plasma Concentration of Vitamin K1 | Vitamin K1 is required by proteins involved in blood clotting. Food interaction with warfarin can lead to decreases in Vitamin K1 in plasma. An increase in vitamin K1 signifies enhancement of warfarin's anticoagulant effect. | All enrolled participants. | Posted | Mean | Full Range | nanogram per liter (ng/L) | Pre-dose on Day 1 and 24 hours post-dose on Day 5 |
|
|
|
| Secondary | Time to Maximum Plasma Concentration (Tmax) for Oseltamivir and Oseltamivir Carboxylate | Oseltamivir carboxylate is an active metabolite of oseltamivir. | All enrolled participants. | Posted | Median | Full Range | hours | Pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours post-dose on Day 1 and 5; 18 and 24 hours post-dose on Day 5 |
|
|
|
| Secondary | Time to Maximum Plasma Concentration (Tmax) for R- and S- Warfarin | All enrolled participants. | Posted | Median | Full Range | hours | Pre-dose; 1, 2, 4, 8, 12, 24 hours post-dose on Day 5 |
|
|
|
| Secondary | Terminal Half-life (t½) for Oseltamivir and Oseltamivir Carboxylate | Oseltamivir carboxylate is an active metabolite of oseltamivir. | All enrolled participants. | Posted | Mean | Standard Deviation | hours | Pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours post-dose on Day 1 and 5; 18 and 24 hours post-dose on Day 5 |
|
|
|
| Secondary | Terminal Half-life (t½) for R- and S- Warfarin | All enrolled participants. | Posted | Mean | Standard Deviation | hours | Pre-dose; 1, 2, 4, 8, 12, 24 hours post-dose on Day 5 |
|
|
|
| Secondary | Oral Plasma Clearance (CL/F) for Oseltamivir | All enrolled participants. | Posted | Mean | Standard Deviation | liters per hour (L/h) | Pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours post-dose on Day 1 and 5; 18 and 24 hours post-dose on Day 5 |
|
|
|
| Secondary | Oral Plasma Clearance (CL/F) for R- and S- Warfarin | All enrolled participants. | Posted | Mean | Standard Deviation | liters per hour (L/h) | Pre-dose; 1, 2, 4, 8, 12, 24 hours post-dose on Day 5 |
|
|
|
| Secondary | Maximum Plasma Concentration (Cmax) for Oseltamivir and Oseltamivir Carboxylate | All enrolled participants. | Posted | Mean | Standard Deviation | nanogram per milliliter (ng/mL) | Pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours post-dose on Day 1 and 5; 18 and 24 hours post-dose on Day 5 |
|
|
|
| Secondary | Maximum Plasma Concentration (Cmax) for R- and S- Warfarin | R- and S-warfarin are two molecular versions of warfarin with slightly different structures. The reported concentrations were normalized by dividing the Cmax values (nanograms per milliliter) by the individual average dose (milligrams). | All enrolled participants. | Posted | Mean | Standard Deviation | Nanogram/milliliter/milligram (ng/mL/mg) | Pre-dose; 1, 2, 4, 8, 12, 24 hours post-dose on Day 5 |
|
|
|
| Secondary | Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero to 24 Hours (AUC0-24h) for Oseltamivir and Oseltamivir Carboxylate | All enrolled participants. | Posted | Mean | Standard Deviation | h*ng/mL | Pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18 and 24 hours post-dose on Day 5 |
|
|
|
| Secondary | Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero to 24 Hours (AUC0-24h) for R- and S- Warfarin | R- and S-warfarin are two molecular versions of warfarin with slightly different structures. The reported concentrations were normalized by dividing the AUC values (hours multiplied by nanograms, per milliliter) by the individual average dose (milligrams). | All enrolled participants. | Posted | Mean | Standard Deviation | h*ng/mL/mg | Pre-dose; 1, 2, 4, 8, 12, 24 hours post-dose on Day 5 |
|
|
|
| Secondary | Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero to 12 Hours (AUC0-12h) for Oseltamivir and Oseltamivir Carboxylate | All enrolled participants. | Posted | Mean | Standard Deviation | h*ng/mL | Pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours post-dose on Day 1 and 5; 18 and 24 hours post-dose on Day 5 |
|
|
|
| Secondary | Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero to 12 Hours (AUC0-12h) for R- and S- Warfarin | R- and S-warfarin are two molecular versions of warfarin with slightly different structures. The reported concentrations were normalized by dividing the AUC values (hours multiplied by nanograms, per milliliter) by the individual average dose (milligrams). | All enrolled participants. | Posted | Mean | Standard Deviation | h*ng/mL/mg | Pre-dose; 1, 2, 4, 8, 12, 24 hours post-dose on Day 5 |
|
|
|
| Secondary | Percentage of Participants With Adverse Events | An adverse event was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. | All enrolled participants. | Posted | Number | percentage of participants | Up to Day 26 |
|
|
|
| 1 |
| 20 |
| 4 |
| 20 |
| EG001 | Warfarin and Oseltamivir | Participants who received warfarin at a prescribed usual dose along with oseltamivir 75 mg, orally twice daily on Days 1-4 and once on Day 5 in treatment period 1 or treatment period 2. | 0 | 20 | 5 | 20 |
| Oral herpes | Infections and infestations | MedDRA (11.0) | Systematic Assessment |
|
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA (11.0) | Systematic Assessment |
|
| Joint effusion | Musculoskeletal and connective tissue disorders | MedDRA (11.0) | Systematic Assessment |
|
| Headache | Nervous system disorders | MedDRA (11.0) | Systematic Assessment |
|
| Diarrhoea | Gastrointestinal disorders | MedDRA (11.0) | Systematic Assessment |
|
| Venipuncture site swelling | General disorders | MedDRA (11.0) | Systematic Assessment |
|
| Hypoglycaemia | Metabolism and nutrition disorders | MedDRA (11.0) | Systematic Assessment |
|
| Pharyngolaryngeal pain | Respiratory, thoracic and mediastinal disorders | MedDRA (11.0) | Systematic Assessment |
|
The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.
| Cyclohexanes |
| D003516 | Cycloparaffins |
| D006840 | Hydrocarbons, Alicyclic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D015110 | 4-Hydroxycoumarins |
| D003374 | Coumarins |
| D001578 | Benzopyrans |
| D011714 | Pyrans |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
|
| Oseltamivir Carboxylate (Steady State: Day 5) |
|
| Total (R)-warfarin |
|
| Free (R)-warfarin |
|
|
| Oseltamivir Carboxylate (Steady State: Day 5) |
|
| Total (R)-warfarin |
|
| Free (R)-warfarin |
|
| Title | Measurements |
|---|---|
|
| Oseltamivir Carboxylate (Steady State: Day 5) |
|
| Total (R)-warfarin |
|
| Free (R)-warfarin |
|
| Total (R)-warfarin |
|
| Free (R)-warfarin |
|
|
| Oseltamivir Carboxylate (Steady State: Day 5) |
|
| Total (R)-warfarin |
|
| Free (R)-warfarin |
|